Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs

that of nocturia which may result from other conditions such as overactive bladder.

About VA111913 and dysmenorrhoea:

VA111913 is an oral small molecule drug candidate in Phase I clinical development for prevention and treatment of dysmenorrhoea, a condition characterized by abnormal contractions of the uterus during menstruation causing severe pain. VA111913 acts by blocking vasopressin 1a receptors in smooth muscle in the uterus wall, which in response to elevated vasopressin levels leads to dysmenorrhoea. VA111913 has demonstrated in preclinical trials it can normalise smooth muscle contraction thereby offering the potential for it to be the first licensed drug that directly targets the cause of this condition in the uterus.

A Phase I trial with VA111913 is underway and expected to report during H1 2009, with Phase II proof of concept studies expected to start in H2 2009, involving up to 150 patients and completing in H2 2010.

Dysmenorrhoea affects a large number of women for whom there are currently no targeted therapies; treatments that are in common use however include over-the-counter painkillers (e.g. naproxen or ibuprofen) or oral contraceptives used 'off-label'. It is estimated that the market opportunity for a targeted drug for the prophylaxis and treatment of dysmenorrhoea is approximately US$1 billion per year.

    Contact details:

    Vantia Therapeutics

    Dr Jim Phillips, CEO              +44(0)238-076-3433         +44(0)7515-397176

    Citigate Dewe Rogerson
    Chris Gardner / Mark Swallow / Helena Galilee
    +44(0)207-638-9571 / /

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
(Date:10/8/2015)... ... 08, 2015 , ... Cystic fibrosis (CF) is a genetic ... and results in dysfunction of the lungs and the gastrointestinal (GI) tract. In ... is very difficult to clear, blocks the airways and the glands, and creates ...
(Date:10/7/2015)... ... 07, 2015 , ... Neil Riordan, PhD to Discuss Medicinal Effects of Mesenchymal ... Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan is one of the ... He is the Co-Founder and Chief Science Officer of the Riordan-McKenna Institute ...
(Date:10/7/2015)... 2015  ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV ) ... the development and commercialization of targeted antiviral therapies, today ... 5,000,000 shares of its common stock and warrants to ... stock at a fixed combined price to the public ... will be issued separately.  The warrants will be exercisable ...
(Date:10/7/2015)... Pa. , Oct. 7, 2015   VWR ... independent provider of laboratory products, services and solutions, ... Inc. (PTI), a specialty solvent company that performs ... This acquisition will enhance VWR,s growing laboratory and ... laboratory and biopharmaceutical manufacturing customers. Manuel ...
Breaking Biology Technology:
... Integra Merger, IRVINE, California, October 24 IsoTis, ... announced that,it has adjourned the special meeting of stockholders ... IsoTis by Integra LifeSciences Holdings,Corporation (NASDAQ: IART ) ... as of August 6, 2007. The special meeting ...
... ALTO, Calif., Oct. 24 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... quarter 2007 financial results on Tuesday, November 6, 2007,following ... host an investor conference call and live audio webcast ... 6, 2007, at 5:00 p.m.,Eastern Time/2:00 p.m. Pacific Time. ...
... 24 /PRNewswire-FirstCall/ - Atrium Innovations Inc. (TSX:,ATB) will ... 10 a.m. Eastern,time on November 8, 2007. The ... third quarter results issued earlier the previous day.,Participants ... numbers:,416-644-3418, 514-807-8791 or 800-591-7539 or via the Company,s ...
Cached Biology Technology:
(Date:9/30/2015)... Calif. , Sept. 30, 2015  With nearly ... the number of new SCIs estimated to reach 12,500 ... Southern California Resource Services for Independent Living ... ILCs in California opening doors ... range of programs and services, notably assistive technology services ...
(Date:9/29/2015)... SUNNYVALE, Calif. , Sept. 29, 2015 ... technology improves employee productivity while also saving energy ... features such as Low Power Active Mode and embedded ... workplace transformation Fujitsu today shows that ... of new and refreshed models to its enterprise desktop ...
(Date:9/28/2015)... Sept. 28, 2015  The monitoring of vital ... body temperature, is an essential component of patient ... of deterioration in a patient,s condition. However, in ... are typically taken during routine observation rounds only ... patient deteriorates between these observation rounds, the warning ...
Breaking Biology News(10 mins):
... it will expand urea deep placement (UDP)a technology that doubles ... (ha) of rice land, reaching about 1.6 million farm families, ... is the insertion of large urea briquettes into the rice ... who use UDP can increase yields by 25% while using ...
... humile, is one of the most successful invasive species in ... to its native range in South America. A new study ... findings, from researchers at the University of Illinois and the ... the Proceedings of the National Academy of Sciences. The ...
... Richard D. Smith, Battelle Fellow at the U.S. Department ... of 50 outstanding leaders in the 2007 Scientific American 50. ... key contributors in science and technology. Smith shared the ... a colleague from UCLAs David Geffen School of Medicine, Desmond ...
Cached Biology News:
... vectors are designed for enhanced translation of cloned ... rabbit reticulocyte lysate. The maps for pCITE-2b(+) and ... following exceptions: pCITE-2b(+) is a 3793 bp plasmid; ... and Xcm I sites. Subtract 7 bp from ...
Biology Products: